FBR & Co reaffirmed their outperform rating on shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in a research note published on Wednesday morning. FBR & Co currently has a $36.00 price objective on the stock.
A number of other research analysts have also issued reports on the stock. HC Wainwright set a $33.00 target price on shares of RedHill Biopharma and gave the company a buy rating in a research note on Friday, October 7th. Zacks Investment Research raised shares of RedHill Biopharma from a sell rating to a hold rating in a research note on Wednesday, September 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $26.20.
RedHill Biopharma (NASDAQ:RDHL) opened at 13.61 on Wednesday. RedHill Biopharma has a 52 week low of $8.10 and a 52 week high of $16.54. The stock’s market capitalization is $173.31 million. The stock’s 50 day moving average is $14.50 and its 200-day moving average is $12.87.
RedHill Biopharma (NASDAQ:RDHL) last posted its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.52. Equities research analysts forecast that RedHill Biopharma will post ($2.06) EPS for the current year.
Several hedge funds have recently modified their holdings of RDHL. Van ECK Associates Corp raised its stake in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares in the last quarter. Ingalls & Snyder LLC acquired a new stake in RedHill Biopharma during the second quarter worth approximately $451,000. Oppenheimer & Co. Inc. acquired a new stake in RedHill Biopharma during the second quarter worth approximately $142,000. Finally, Royal Bank of Canada increased its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares during the last quarter. 15.30% of the stock is owned by institutional investors.
About RedHill Biopharma